$ABT ABBOTTS beats on earnings but we expect pullback
152
Abbotts quite simply does not miss earnings, a fantastic company and fantastic product in the ever increasing market of Diabetes treatment. Despite this we see a little stagnant price action lately and a pullback is quite possible.